Functional genomics to identify unforeseen cancer drug targets

Future Oncology

Volumn 9, Issue 4, 2013, Pages 473-476

  Kemp, Christopher J ^a   Grandori, Carla ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

cancer drug target; functional genomics; high throughput screening; RNAi screening; synthetic lethality

Indexed keywords

ABELSON KINASE; ANTIMITOTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE C; PROTEIN P53;

BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; CELL CYCLE REGULATION; CELL DEATH; CIRCADIAN RHYTHM; DNA DAMAGE; DNA REPAIR; DNA SEQUENCE; DNA SYNTHESIS; DRUG DEVELOPMENT; DRUG INDUSTRY; FOLLOW UP; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REVIEW; RHYTHM; RNA INTERFERENCE; ROBOTICS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZAMIDES; BREAST NEOPLASMS; CASEIN KINASE I; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; GENES, MYC; GENES, RAS; GENOMICS; HUMANS; LEUKEMIA; MICE; MOLECULAR TARGETED THERAPY; MUTATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; RECEPTOR, ERBB-2; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84875959928     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.26     Document Type: Review

References (23)

1. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 278(5340), 1064-1068 (1997). (Pubitemid 27517876)
2. Dixon SJ, Costanzo M, Baryshnikova A, Andrews B, Boone C, Systematic mapping of genetic interaction networks. Ann. Rev. Genet. 43, 601-625 (2009).
3. Gurley KE, Kemp CJ, Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Curr. Biol. 11(3), 191-194 (2001). (Pubitemid 32152105)
4. Gurley KE, Moser R, Gu Y, Hasty P, Kemp CJ. DNA-PK suppresses a p53-independent apoptotic response to DNA damage. EMBO Rep. 10(1), 87-93 (2009).
5. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23(16), 1895-1909 (2009).
6. Moser R, Toyoshima M, Robinson K, et al. MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol. Cancer Res. 10(4), 535-545 (2012).
7. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
8. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998). (Pubitemid 28099681)
9. Paddison PJ, Silva JM, Conklin D, et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428(6981), 427-431 (2004). (Pubitemid 38419688)
10. Bartz SR, Zhang Z, Burchard J, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26(24), 9377-9386 (2006). (Pubitemid 44904431)
11. Kaelin WG. Cell biology: divining cancer cell weaknesses. Nature 441(7089), 32-34 (2006).
12. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5(9), 689-698 (2005). (Pubitemid 41486362)
13. Boehm JS, Hahn WC. Towards systematic functional characterization of cancer genomes. Nat. Rev. Genet. 12(7), 487-498 (2011).
14. Toyoshima M, Howie HL, Imakura M, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc. Natl Acad. Sci. USA 109(24), 9545-9550 (2012).
15. Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335(6066), 348-353 (2012).
16. Liu L, Ulbrich J, Müller J, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483(7391), 608-612 (2012).
17. Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149(3), 642-655 (2012).
18. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5), 835-848 (2009).
19. Brough R, Frankum JR, Sims D, et al. Functional viability profiles of breast cancer. Cancer Discov. 1(3), 260-273 (2011).
20. Sprouse J, Reynolds L, Kleiman R, Tate B, Swanson TA, Pickard GE. Chronic treatment with a selective inhibitor of casein kinase I delta/epsilon yields cumulative phase delays in circadian rhythms. Psychopharmacology (Berl.) 210(4), 569-576 (2010).
21. Matsunaga S, Ikeda M, Kishi T, et al. An evaluation of polymorphisms in casein kinase 1 delta and epsilon genes in major psychiatric disorders. Neurosci. Lett. 529(1), 66-69 (2012).
22. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011).
23. Telleria CM. Drug repurposing for cancer therapy. J. Cancer Sci. Ther. 4(7), ix-xi (2012).